s12872-016-0344-x.pdf (649.98 kB)
Sharing success - understanding barriers and enablers to secondary prophylaxis delivery for rheumatic fever and rheumatic heart disease
journal contributionposted on 17.01.2021, 23:33 by J Chamberlain-Salaun, Jane Mills, PM Kevat, MGW Rémond, GP Maguire
© 2016 The Author(s). Background: Rheumatic fever (RF) and rheumatic heart disease (RHD) cause considerable morbidity and mortality amongst Australian Aboriginal and Torres Strait Islander populations. Secondary antibiotic prophylaxis in the form of 4-weekly benzathine penicillin injections is the mainstay of control programs. Evidence suggests, however, that delivery rates of such prophylaxis are poor. Methods: This qualitative study used semi-structured interviews with patients, parents/care givers and health professionals, to explore the enablers of and barriers to the uptake of secondary prophylaxis. Data from participant interviews (with 11 patients/carers and 11 health practitioners) conducted in four far north Queensland sites were analyzed using the method of constant comparative analysis. Results: Deficits in registration and recall systems and pain attributed to injections were identified as barriers to secondary prophylaxis uptake. There were also varying perceptions regarding responsibility for ensuring injection delivery. Enablers of secondary prophylaxis uptake included positive patient-healthcare provider relationships, supporting patient autonomy, education of patients, care givers and healthcare providers, and community-based service delivery. Conclusion: The study findings provide insights that may facilitate enhancement of secondary prophylaxis delivery systems and thereby improve uptake of secondary prophylaxis for RF/RHD.
This study was supported by: the HeartKids Australia Grants-In-Aid Program supported by the Wilson HTM Foundation; the National Health and Medical Research Council (NHMRC) Centres for Research Excellence to Reduce Inequality in Heart Disease and END RHD; and the Victorian Government's Operational Infrastructure Support Program. Graeme Maguire is supported by an NHMRC Practitioner Fellowship. The funding bodies had no role in the design of the study, collection, analysis and interpretation of data, or in writing the manuscript.
JournalBMC Cardiovascular Disorders
Article NumberARTN 166
PublisherBIOMED CENTRAL LTD
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineCardiac & Cardiovascular SystemsCardiovascular System & CardiologyRheumatic feverRheumatic heart diseaseSecondary prophylaxisBenzathine penicillinPenicillinNORTHERN-TERRITORYFOLLOW-UPAUSTRALIABURDENHumansRheumatic FeverRheumatic Heart DiseaseAnti-Bacterial AgentsMorbidityQueenslandFemaleMaleSecondary PreventionPenicillin G BenzathineQuality ImprovementSurveys and QuestionnairesCardiovascular System & Hematology